Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics.

MLA

Jiang, Shanshan, et al. “Discriminating MGMT Promoter Methylation Status in Patients with Glioblastoma Employing Amide Proton Transfer-Weighted MRI Metrics.” European Radiology, vol. 28, no. 5, May 2018, pp. 2115–23. EBSCOhost, https://doi.org/10.1007/s00330-017-5182-4.

APA

Jiang, S., Rui, Q., Wang, Y., Heo, H.-Y., Zou, T., Yu, H., Zhang, Y., Wang, X., Du, Y., Wen, X., Chen, F., Wang, J., Eberhart, C. G., Zhou, J., & Wen, Z. (2018). Discriminating MGMT promoter methylation status in patients with glioblastoma employing amide proton transfer-weighted MRI metrics. European Radiology, 28(5), 2115–2123. https://doi.org/10.1007/s00330-017-5182-4

Chicago

Jiang, Shanshan, Qihong Rui, Yu Wang, Hye-Young Heo, Tianyu Zou, Hao Yu, Yi Zhang, et al. 2018. “Discriminating MGMT Promoter Methylation Status in Patients with Glioblastoma Employing Amide Proton Transfer-Weighted MRI Metrics.” European Radiology 28 (5): 2115–23. doi:10.1007/s00330-017-5182-4.